JP5926685B2 - 二光子光増感剤、それらを含むナノ粒子および薬物としてのそれらの使用 - Google Patents

二光子光増感剤、それらを含むナノ粒子および薬物としてのそれらの使用 Download PDF

Info

Publication number
JP5926685B2
JP5926685B2 JP2012543599A JP2012543599A JP5926685B2 JP 5926685 B2 JP5926685 B2 JP 5926685B2 JP 2012543599 A JP2012543599 A JP 2012543599A JP 2012543599 A JP2012543599 A JP 2012543599A JP 5926685 B2 JP5926685 B2 JP 5926685B2
Authority
JP
Japan
Prior art keywords
group
nanoparticles
defined above
carbon atoms
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012543599A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013513632A (ja
JP2013513632A5 (enExample
Inventor
ブレヴェット，ディヴィッド
レイム，ローレンス
ブランチャード−デセ，ミレイユ
モンジン，オリビエ
ゲイリー−ボボ−サブレ−テシャン，マガリ
ガルシア，マルセル
モレレ，アライン
ドュラン，ジャン−オリビエ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Montpellier
Original Assignee
University of Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Montpellier filed Critical University of Montpellier
Publication of JP2013513632A publication Critical patent/JP2013513632A/ja
Publication of JP2013513632A5 publication Critical patent/JP2013513632A5/ja
Application granted granted Critical
Publication of JP5926685B2 publication Critical patent/JP5926685B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0801—General processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
JP2012543599A 2009-12-15 2010-12-07 二光子光増感剤、それらを含むナノ粒子および薬物としてのそれらの使用 Expired - Fee Related JP5926685B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09306238 2009-12-15
EP09306238.8 2009-12-15
PCT/EP2010/069035 WO2011073054A1 (en) 2009-12-15 2010-12-07 Biphotonic photosensitizers, nanoparticles containing the same and their use as drugs

Publications (3)

Publication Number Publication Date
JP2013513632A JP2013513632A (ja) 2013-04-22
JP2013513632A5 JP2013513632A5 (enExample) 2014-01-30
JP5926685B2 true JP5926685B2 (ja) 2016-05-25

Family

ID=42021128

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012543599A Expired - Fee Related JP5926685B2 (ja) 2009-12-15 2010-12-07 二光子光増感剤、それらを含むナノ粒子および薬物としてのそれらの使用

Country Status (5)

Country Link
US (1) US8709747B2 (enExample)
EP (1) EP2513083B1 (enExample)
JP (1) JP5926685B2 (enExample)
CA (1) CA2784212C (enExample)
WO (1) WO2011073054A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2988721B1 (fr) 2012-03-27 2014-04-04 Centre Nat Rech Scient Nanoparticules de silicium poreux fonctionnalisees et leurs utilisations en therapie photodynamique
FR3044676B1 (fr) * 2015-12-04 2017-11-24 Univ Rennes Dendrimeres photosensibilisateurs biphotoniques, procede de fabrication et utilisations
CN111818944A (zh) * 2017-12-08 2020-10-23 南洋理工大学 具有光动力活性的有机二氧化硅纳米粒子及其医学用途
WO2022100750A1 (zh) * 2020-11-16 2022-05-19 北京厚燊维康科技有限责任公司 可用于光动力治疗或诊断的制剂
CN117327098B (zh) * 2023-09-28 2025-11-11 江汉大学 一种以用于i型光动力治疗为主的aie型光敏剂的制备方法与应用
WO2025207959A1 (en) 2024-03-27 2025-10-02 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITFI940095A1 (it) * 1994-05-23 1995-11-23 Molteni & C Coniugati fotodinamici aventi proprieta' biocide
AU2004207813B8 (en) * 2003-01-24 2010-04-22 Health Research, Inc. Use of photodynamic therapy therapeutic agents entrapped in ceramic nanoparticles
WO2008030624A2 (en) 2006-09-08 2008-03-13 The Research Foundation Of State University Of New York Nanoparticles for two-photon activated photodynamic therapy and imaging

Also Published As

Publication number Publication date
CA2784212A1 (en) 2011-06-23
EP2513083B1 (en) 2016-04-06
WO2011073054A1 (en) 2011-06-23
US8709747B2 (en) 2014-04-29
CA2784212C (en) 2018-01-16
JP2013513632A (ja) 2013-04-22
US20130065849A1 (en) 2013-03-14
EP2513083A1 (en) 2012-10-24

Similar Documents

Publication Publication Date Title
Pechnikova et al. Carbon quantum dots in biomedical applications: advances, challenges, and future prospects
Xu et al. Hypoxia-activated NIR photosensitizer anchoring in the mitochondria for photodynamic therapy
Zhang et al. Intrinsically cancer-mitochondria-targeted thermally activated delayed fluorescence nanoparticles for two-photon-activated fluorescence imaging and photodynamic therapy
Zhang et al. Graphene oxide decorated with Ru (II)–polyethylene glycol complex for lysosome-targeted imaging and photodynamic/photothermal therapy
Wang et al. Hexagonal boron nitride nanomaterials for biomedical applications
Kang et al. Good steel used in the blade: well‐tailored type‐I photosensitizers with aggregation‐induced emission characteristics for precise nuclear targeting photodynamic therapy
Yang et al. A folate-conjugated platinum porphyrin complex as a new cancer-targeting photosensitizer for photodynamic therapy
Yuan et al. Imaging-guided synergistic photo-chemotherapy using doxorubicin-loaded gadolinium porphyrin-based metal–organic framework nanosheets
Pan et al. Near-infrared AIE-active phosphorescent iridium (III) complex for mitochondria-targeted photodynamic therapy
CN103827020B (zh) α-形式锌-酞菁纳米线、α-形式锌-酞菁纳米线/吩噻嗪复合体的制备方法
JP2013513632A (ja) 二光子光増感剤、それらを含むナノ粒子および薬物としてのそれらの使用
Hu et al. A thermally activated delayed fluorescence photosensitizer for photodynamic therapy of oral squamous cell carcinoma under low laser intensity
Chen et al. A mitochondria-localized iridium (III)–chlorin E6 conjugate for synergistic sonodynamic and two-photon photodynamic therapy against melanoma
Nalepa et al. A [60] fullerene nanoconjugate with gemcitabine: synthesis, biophysical properties and biological evaluation for treating pancreatic cancer
Zhang et al. Near infrared light triggered reactive oxygen species responsive nanoparticles for chemo-photodynamic combined therapy
Xia et al. Near-infrared organic fluorescent nanoparticles for long-term monitoring and photodynamic therapy of cancer
WO2015026963A2 (en) Phthalocy anine-dendrimer compositions and a method of using
Zhang et al. Multifunctional tetracene/pentacene host/guest nanorods for enhanced upconversion photodynamic tumor therapy
KR20200081621A (ko) 광감작제를 포함하는 자기 조립 나노입자 및 이를 포함하는 광역학 치료용 조성물
Nisa et al. Applications of supramolecular assemblies in drug delivery and photodynamic therapy
Sun et al. A multi-parameter-induced activation of gas therapeutic platform to remarkably amplify photodynamic therapy efficacy
Xu et al. A unique chemo-photodynamic antitumor approach to suppress hypoxia via ultrathin graphitic carbon nitride nanosheets supported a platinum (IV) prodrug
Hou et al. GSH-activatable camptothecin prodrug-loaded gold nanostars coated with hyaluronic acid for targeted breast cancer therapy via multiple radiosensitization strategies
CN116478196A (zh) 氟硼类化合物及其制备方法、应用、线粒体靶向型光敏剂
US20200140466A1 (en) Mesoporous organosilica nanoparticles, production method thereof and uses of same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131203

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20141030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151224

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160329

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160422

R150 Certificate of patent or registration of utility model

Ref document number: 5926685

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees